“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer - Episode 3

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

September 23, 2020
Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology

Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

Susan Hays, ANP, Washington University Siteman Cancer Center

Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute

Challenges for patients diagnosed with metastatic HER2+ breast cancer and recent FDA approved-therapies for the third-line setting are reviewed.